BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 21674066)

  • 1. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of adaptation to human tetherin in HIV-1 group O and P.
    Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
    Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmembrane interactions of HIV-1 Vpu and tetherin.
    Guo F; Liang C
    Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
    Yoshida T; Koyanagi Y; Strebel K
    J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA.
    Lv M; Zhu Y; Wang J; Zhang H; Wang X; Zuo T; Liu D; Zhang J; Wu J; Kong W; Yu X
    Protein Expr Purif; 2013 Oct; 91(2):112-8. PubMed ID: 23916489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
    J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
    Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
    J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
    Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
    J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.
    Vigan R; Neil SJ
    J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.